GlassScriptPhysician profile
Jill Gilman
NPI 1396463725
$1,296.93
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $227 · 2023: $730 · 2024: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.95 | 2022-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Glaxosmithkline, LLC. | $204.92 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $166.17 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $120.32 | 2022-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $108.72 | 2023-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $103.67 | 2023-2024 | Wegovy |
| Exact Sciences Corporation | $82.18 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.42 | 2023-2024 | Xifaxan, Trulance |
| Lundbeck LLC | $48.32 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $43.86 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.42 | 2022-2023 | Trintellix |
| Amgen INC. | $32.53 | 2023-2024 | Repatha, Otezla, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $25.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.59 | 2023 | Rexulti |
| Pfizer INC. | $16.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Gilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.